mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.025 |
0.4 |
mRNA |
Crizotinib |
CTRPv2 |
pan-cancer |
AAC |
0.025 |
0.4 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.027 |
0.4 |
mRNA |
BRD-K99006945 |
CTRPv2 |
pan-cancer |
AAC |
-0.04 |
0.4 |
mRNA |
nakiterpiosin |
CTRPv2 |
pan-cancer |
AAC |
-0.025 |
0.4 |
mRNA |
BRD-K64610608 |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
pifithrin-alpha |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
tamatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.028 |
0.4 |
mRNA |
BRD9647 |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
BCL-LZH-4 |
CTRPv2 |
pan-cancer |
AAC |
-0.04 |
0.4 |